| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Chief Commercial Officer | Restricted Stock Units | 16,385 | $1,014,482 | $131.07 | 26 Feb 2026 | Direct |
| Axsome Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 0 | $0 | $184.44 | 21 Jan 2026 | Direct |
| Axsome Therapeutics, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 31,210 | 21 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | 26 Feb 2026 | 1 | $0 | 4 | Chief Commercial Officer | 27 Feb 2026, 19:10 |
| AXSM | Axsome Therapeutics, Inc. | 21 Jan 2026 | 3 | -$852,825 | 4 | Chief Commercial Officer | 23 Jan 2026, 19:00 |
| AXSM | Axsome Therapeutics, Inc. | 21 Feb 2025 | 3 | $0 | 4 | Chief Commercial Officer | 25 Feb 2025, 19:57 |
| AXSM | Axsome Therapeutics, Inc. | 14 Oct 2024 | 0 | $0 | 3 | Chief Commercial Officer | 24 Oct 2024, 18:23 |